Cabio Biotech (Wuhan) Management
Management criteria checks 4/4
Cabio Biotech (Wuhan)'s CEO is Dewei Yi, appointed in Dec 2015, has a tenure of 9.17 years. directly owns 1.39% of the company’s shares, worth CN¥46.74M. The average tenure of the management team and the board of directors is 9.2 years and 6.2 years respectively.
Key information
Dewei Yi
Chief executive officer
CN¥1.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 9.2yrs |
| CEO ownership | 1.4% |
| Management average tenure | 9.2yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
CEO
Dewei Yi (59 yo)
9.2yrs
Tenure
CN¥1,090,600
Compensation
Mr. Dewei Yi is Chairman and General Manager of CABIO Biotech(Wuhan) Co., Ltd., since December 2015. From December 1999 he has been the chairman of Wuhan Xiwang Biological Engineering Co., Ltd.; since Nove...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 9.2yrs | CN¥1.09m | 1.39% CN¥ 46.7m | |
| Financial Director & Director | 9.2yrs | CN¥781.40k | 0.66% CN¥ 22.2m | |
| Deputy GM & Secretary of the Board of Directors | no data | CN¥640.10k | 0.089% CN¥ 3.0m | |
| Deputy General Manager | 3.9yrs | CN¥713.40k | 0.098% CN¥ 3.3m | |
| Deputy General Manager | 3.2yrs | CN¥862.90k | 0.14% CN¥ 4.8m | |
| Deputy General Manager | 9.2yrs | CN¥763.90k | 0.12% CN¥ 4.1m | |
| Deputy General Manager | 9.2yrs | CN¥640.90k | 0.093% CN¥ 3.2m | |
| Accounting Supervisor | no data | no data | no data |
9.2yrs
Average Tenure
48yo
Average Age
Experienced Management: 688089's management team is seasoned and experienced (9.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 9.2yrs | CN¥1.09m | 1.39% CN¥ 46.7m | |
| Financial Director & Director | 9.2yrs | CN¥781.40k | 0.66% CN¥ 22.2m | |
| Vice Chairman | 9.2yrs | CN¥984.80k | 0.58% CN¥ 19.6m | |
| Employee Representative Supervisor | 9.2yrs | no data | 0.018% CN¥ 613.2k | |
| Director | 3.2yrs | no data | no data | |
| Independent Director | 3.2yrs | CN¥80.00k | no data | |
| Independent Director | 3.2yrs | CN¥80.00k | no data | |
| Supervisor | 3.2yrs | no data | no data |
6.2yrs
Average Tenure
53.5yo
Average Age
Experienced Board: 688089's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/04 01:06 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cabio Biotech (Wuhan) Co., Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wendan Wang | China International Capital Corporation Limited |
| Zhuonan Xu | China International Capital Corporation Limited |
| Yifan Du | Citic Securities Co., Ltd. |